Menu
Recruiting NCT07400926

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg

— Observational Open Angle Glaucoma (OAG) Ocular Hypertension (OH)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Travoprost.
Who it may be relevant to
Registry conditions: Open Angle Glaucoma (OAG), Ocular Hypertension (OH). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg

Overview

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

Detailed description

The objective of this study is to evaluate the administration of the Travoprost intracameral implant using the updated inserter (Model G2-TRIO)

Interventions

  • Combination product Travoprost
    Travoprost intracameral implant, 75mcg administered using the sterile, single-dose updated inserter (Model G2-TRIO)

Primary outcome measures

  • Successful implantation [Time frame: 1 day]

Eligibility criteria

Inclusion criteria

  • Diagnosis of Open-angle glaucoma
  • 18 years of age or older

Exclusion criteria

  • Subject who is breast-feeding or pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Glaukos Investigative Site — Kenosha

Identifiers

NCT: NCT07400926 · GLK-101-03

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗